X

Drug Profile

Perflexane

Alternative Names: AF0150; AFO 150; Imagent; Imavist

Latest Information Update: 09 Dec 2004

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IMCOR Pharmaceutical
Class Fluorocarbons; Imaging agents; Small molecules
Mechanism of Action Cell membrane permeability enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Marketed Cardiovascular disorders

Most Recent Events

09 Dec 2004 IMCOR commenced a phase II study investigating alternative methods of administration for perflexane such as repeat dosing and infusion
12 Feb 2004 Photogen Technologies is now called IMCOR Pharmaceutical
22 Dec 2003 Perflexane has been licensed to Kyosei Pharmaceutical Co. Ltd. for radiology and cardiology indications in Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com